You are viewing a historical snapshot of United Kingdom (London Stock Exchange). These figures are a preview to show what TradeTidings covers. Live, continuously updated United Kingdom sentiment and stock impact is a Pro feature.
Get live United Kingdom data with ProAstraZeneca (AZN)
61 stories published on AZN since June 2026. See all coverage.
News sentiment trend
Counts of positive, neutral, and negative news items over the last 90 days. Not a price chart.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
Sentiment timeline
How news sentiment on AstraZeneca (AZN) has built up over time. Each bar sums the direction of every story TradeTidings published in the period, weighted by how influential we rated it, not just a plain count, so a single high-influence negative story can outweigh several small positive ones. Hover a bar for its exact figures, or click one to filter the stories below to that period. Our own original analysis, not a copied index or a price chart, and not a prediction.
Why this reading
The recent items weighing most on this reading, by direction and influence.
AstraZeneca Stock in Focus as Drug Trial Failure Wipes £20 Billion Off Value
Direct news · High influence · Long term
AstraZeneca's Enhertu Cancer Drug Gains Approval, Boosting Prospects
Direct news · High influence · Long term
AstraZeneca Secures Two EU Cancer Approvals, Advances Lung Cancer Trial
Direct news · High influence · Long term
AstraZeneca Rallies on Oncology Approval and Pipeline Optimism
Direct news · High influence · Long term
AstraZeneca Signs $1.77 Billion Drug Development Deal with China's CSPC
Direct news · High influence · Long term
Direct news
The most recent stories naming AZN directly, across all of our coverage.
AstraZeneca Half-Year Profit Beat Eases Pipeline Worries: AZN Stock in Focus
AstraZeneca Stock: AZN Seeks EU Approval for Trixeo Aerosphere
EU Clears AstraZeneca's Etcamah Combination for First Line Breast Cancer
AstraZeneca Stock: Shares Slide After Rare Clinical Trial Failure
AstraZeneca Moves Closer to EU Approval of Trixeo Aerosphere for Asthma
AstraZeneca Stock: EU Approves New Breast Cancer Treatment
AstraZeneca Stock Slides After Clinical Trial Failure
AstraZeneca Wins EU Approval for Etcamah
Royalty pens $425M deal for slice of AstraZeneca ATTR drug sales
AstraZeneca Stock: New Deal Adds Lung Cancer Drug Worth Up to $1.5 Billion
AstraZeneca Stock in Focus After 1.5 Billion Dollar Dizal Lung Cancer Deal
AstraZeneca Stock in Focus After Azcuris Deal for Oral Asthma and Eczema Drug
AstraZeneca Stock Falls as HSBC Downgrades After Wainua Trial Miss
AstraZeneca Stock in Focus as Sino Biopharm Licensing Deal Adds to China Pipeline
AstraZeneca Trial Setback Puts Pipeline Premium Under Scrutiny
AstraZeneca Stock in Focus as ATTR-CM Trial Failure Aids Rival Pfizer
AstraZeneca Stock in Focus as Rival Padcev Keytruda Combo Wins Wider FDA Approval in Bladder Cancer
AstraZeneca Stock in Focus as Drug Trial Failure Wipes £20 Billion Off Value
AstraZeneca Wins US Appeals Court Ruling in Pfizer Cancer Drug Patent Fight
AstraZeneca and Ionis Heart Drug Wainua Falls Short in Trial
AstraZeneca Shares Slip After Ionis-Partnered Heart Trial Misses Goal
AstraZeneca Stock Slides on Ionis Trial Miss, but Setback May Be Overstated
AstraZeneca Wainua Trial Setback With Ionis Clouds Pipeline Growth
AstraZeneca Shares Fall After a Clinical Trial Setback
AstraZeneca Buys Ex-China Rights to Sino Biopharm COPD Drug for $2.1bn
AstraZeneca Signs Multi-Year Genomics Data Deal With Helix
AstraZeneca Nears NICE Pricing Deal for Enhertu Breast Cancer Drug
AstraZeneca Nears UK Price Deal With Daiichi For Cancer Drug Enhertu
AstraZeneca Pays $200m Upfront for Sino Biopharmaceutical COPD Drug
AstraZeneca and GSK Sign Separate Respiratory Licensing Deals With Sino Biopharm
AstraZeneca's Durvalumab Fails Lung Cancer Survival Trial
AstraZeneca Signs Up to 1.9 Billion Dollar Respiratory Deal With Sino Biopharma
AstraZeneca's Baxfendy Set for Blockbuster Sales After Hypertension Approval
AstraZeneca Signs Multi-Year Genomics Deal With Helix for Drug Discovery
Astrazeneca returns to tap China’s CSPC in $1.7B discovery deal
AstraZeneca Partners with Abbisko on Lung Cancer Drug Combination After China Trial Clearance
AstraZeneca's Enhertu Cancer Drug Gains Approval, Boosting Prospects
AstraZeneca Secures $1.7 Billion Kidney Drug Discovery Deal with Chinese Partner CSPC
AstraZeneca Collaborates on NSCLC Trial: Pipeline Expansion in Focus
AstraZeneca Secures Near $1.8 Billion Renal Disease Drug Deal with CSPC, Boosting Pipeline
AstraZeneca Secures Two EU Cancer Approvals, Advances Lung Cancer Trial
AstraZeneca Secures New $1.7 Billion Pact with CSPC: Pharmaceutical Stock in Focus
AstraZeneca Rallies on Oncology Approval and Pipeline Optimism
AstraZeneca Signs $1.77 Billion Drug Development Deal with China's CSPC
AstraZeneca taps China’s CSPC again, betting up to $1.77B to target kidney diseases
AstraZeneca Signs China Deal for Kidney Drugs: Pipeline Expansion in Focus
AstraZeneca Partners with CSPC for Renal Disease Drug in China, Boosting Pipeline
CSPC Pharmaceutical Enters Collaboration, Option & License Agreement With Astrazeneca For siRNA Drugs
AstraZeneca Begins Phase I/II Lung Cancer Drug Trial: Pipeline Boost for AZN
Abbisko, AstraZeneca Begin Phase I/II Trial of Lumipodlin With Osimertinib in EGFR-Mutant NSCLC
AstraZeneca Collaborates on Lung Cancer Drug Trial: AZN Shares in Focus
China's CSPC and AstraZeneca sign $1.77b drug development deal - China Daily
AstraZeneca Pays $34M to Settle Texas Kickback Lawsuit Over Free Nurses
AstraZeneca Secures EU Approval for Enhertu Cancer Treatment: Positive for Pharma Stock
AstraZeneca Unveils Strong Phase 3 Bone Disease Drug Data, Targeting $5 Billion Sales
AstraZeneca's Enhertu Wins EU Tumour-Agnostic Approval for HER2-Positive Cancers
AstraZeneca's Datroway Wins EU Regulator's Recommendation as First-Line Breast Cancer Treatment
AstraZeneca Faces German Drug Pricing Pressure, Lung Trial Results Awaited
AstraZeneca Daily Weight Loss Pill Shows Promising Trial Results
AstraZeneca Expands Obesity Drug Pipeline and Genetic Medicine Investment: Pharma Stock in Focus
Indirect drivers in the news
Macro, commodity, FX and regulatory forces that have moved AZN, with the stories behind each.
No indirect-driver news for AZN in our coverage yet.
Also monitored for AZN (no news in our coverage yet): US Fed / global rates & risk, UK Budget / fiscal & tax, Drug approvals & trial outcomes, Sterling (GBP).
See the full picture
Sign up free to track AZN, unlock full history and the complete driver breakdown, and get alerts when sentiment shifts.
Track AZN for freeInformational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.